ANXA2 and hepatocellular carcinoma: When ANXA2 expression is effectively inhibited, the growth and motility of both the human colorectal cancer cell line CACO2 and human hepatocellular carcinoma cell line SMMC7721 are significantly reduced, and the motility-associated microstructures, such as pseudopods and filamentous pseudopods, as well as the polymerisation of microfilaments and microtubules, are significantly inhibited (He et al., 2019).